bluuebunny/crossref_metadata_2025_split huggingface dataset:
Accessibility to ERCP‐performing hospitals among patients with pancreatic cancer living in SEER regions
Authors: Tavakkoli Anna , Beauchamp Alaina , Prasad Tanushree , Zhu Hong , Singal Amit G. , Elmunzer B. Joseph , Kubiliun Nisa M. , Kwon Richard S. , Hughes Amy E. , Pruitt Sandi L. 
Published: February 2024

AbstractBackground and AimsThe two most common interventions used to treat painless jaundice from pancreatic cancer are endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic biliary drainage (PTBD). Our study aimed to characterize the geographic distribution of ERCP‐performing hospitals among patients with pancreatic cancer in the United States and the association between geographic accessibility to ERCP‐performing hospitals and biliary interventions patients receive.MethodsThis is a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER)‐Medicare database for pancreatic cancer from 2005 to 2013. Multilevel models were used to examine the association between accessibility to ERCP hospitals within a 30‐ and 45‐min drive from the patient's residential ZIP Code and the receipt of ERCP treatment. A two‐step floating catchment area model was used to calculate the measure of accessibility based on the distribution across SEER regions.Results7464 and 782 patients underwent ERCP and PTBD, respectively, over the study period. There were 808 hospitals in which 8246 patients diagnosed with pancreatic cancer in SEER regions from 2005 to 2013 received a procedure. Patients with high accessibility within both 30‐ and 45‐min drive to an ERCP‐performing hospital were more likely to receive an ERCP (30‐min adjusted odds ratio [aOR]: 1.53, 95% confidence interval [CI]: 1.17–2.01; 45‐min aOR: 1.31, 95% CI: 1.01–1.70). Furthermore, in the adjusted model, Black patients (vs. White) and patients with stage IV disease were less likely to receive ERCP than PTBD.ConclusionsPatients with pancreatic cancer and high accessibility to an ERCP‐performing hospital were more likely to receive ERCP. Disparities in the receipt of ERCP persisted for Black patients regardless of their access to ERCP‐performing hospitals.
Association between personality types and low anterior resection syndrome in rectal cancer patients following surgery
Authors: Chiang Ting‐Yu , Hsu Yu‐Jen , Chern Yih‐Jong , Liao Chun‐Kai , Tsai Wen‐Sy , Hsieh Pao‐Shiu , Hsu Hung‐Chih , Lin Yu‐Fen , Lee Hsiu‐Lan , You Jeng‐Fu 
Published: February 2024

AbstractPurposeLow anterior resection syndrome (LARS) has had many impacts on the lives of patients and substantial differences in emotional and social functions. The aim of this study was to investigate the correlation analysis of different personality traits in rectal cancer patients with LARS after undergoing curative surgery.MethodsThis study was designed as a prospective cohort study. The inclusion criteria included (1) participants diagnosed with rectal cancer who underwent surgical resection of malignant tumors and (2) ECOG 0–1. The primary outcome was the correlation between different personality traits and low anterior resection syndrome in rectal cancer patients after radical surgery. Low anterior resection syndrome incidence rates were estimated by questionnaires and personality groups by the Type A and Type D Scale‐14 Personality Inventory.ResultsFor all 161 participants in this study, the presence of a tumor at the lower anal verge and the receipt of neoadjuvant CCRT had a statistically significant positive correlation with the LARS score at 1 month, 6 months, and 1 year (Pearson correlation coefficient = −0.283, −0.374, and − 0.205, respectively), with a p value of less than 0.05. Personalities with Type A, Type D, and Type D‐SI scores had a statistically significant positive correlation with LARS score at 1 month (Pearson correlation coefficient = 0.172, 0.162, and 0,164, p value = 0.03, 0.04, and 0.04).ConclusionType A and Type D personalities are highly linked to LARS. Personalized support approaches can ultimately assist rectal cancer patients in overcoming difficulties after surgery and recovery and enhance their functional outcomes.
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada
Authors: Judd Sandra , Revon‐Riviere Gabriel , Grover Stephanie A. , Deyell Rebecca J. , Vanan Magimairajan Issai , Lewis Victor A. , Pecheux Lucie , Zorzi Alexandra P. , Goudie Catherine , Santiago Raoul , Tran Thai Hoa , Abbott Lesleigh S. , Brossard Josee , Moorehead Paul , Alvi Saima , Portwine Carol , Denburg Avram , Whitlock James A. , Cohen‐Gogo Sarah , Morgenstern Daniel A. 
Published: February 2024

AbstractBackgroundThe need for new therapies to improve survival and outcomes in pediatric oncology along with the lack of approval and accessible clinical trials has led to “out‐of‐trial” use of innovative therapies. We conducted a retrospective analysis of requests for innovative anticancer therapy in Canadian pediatric oncology tertiary centers for patients less than 30 years old between 2013 and 2020.MethodsInnovative therapies were defined as cancer‐directed drugs used (a) off‐label, (b) unlicensed drugs being used outside the context of a clinical trial, or (c) approved drugs with limited evidence in pediatrics. We excluded cytotoxic chemotherapy, cellular products, and cytokines.ResultsWe retrieved data on 352 innovative therapy drug requests. Underlying diagnosis was primary CNS tumor 31%; extracranial solid tumor 37%, leukemia/lymphoma 22%, LCH 2%, and plexiform neurofibroma 6%. RAS/MAP kinase pathway inhibitors were the most frequently requested innovative therapies in 28% of all requests followed by multi‐targeted tyrosine kinase inhibitors (17%), inhibitors of the PIK3CA‐mTOR‐AKT pathway (8%), immune checkpoints inhibitors (8%), and antibody drug conjugates (8%). In 112 out of 352 requests, innovative therapies were used in combination with another anticancer agent. 48% of requests were motivated by the presence of an actionable molecular target. Compassionate access accounted for 52% of all requests while public insurance was used in 27%. Mechanisms of funding varied between provinces.ConclusionThis real‐world data collection illustrates an increasing use of “out‐of‐trial” innovative therapies in pediatric oncology. This new field of practice warrants further studies to understand the impact on patient trajectory and equity in access to innovative therapies.
Prediction for oxaliplatin‐induced liver injury using patient‐derived liver organoids
Authors: Tatsumi Kumiko , Wada Hiroshi , Hasegawa Shinichiro , Asukai Kei , Nagata Shigenori , Ekawa Tomoya , Akazawa Takashi , Mizote Yu , Okumura Shintaro , Okamura Ryosuke , Ohue Masayuki , Obama Kazutaka , Tahara Hideaki 
Published: February 2024

AbstractBackgroundLiver injury associated with oxaliplatin (L‐OHP)‐based chemotherapy can significantly impact the treatment outcomes of patients with colorectal cancer liver metastases, especially when combined with surgery. To date, no definitive biomarker that can predict the risk of liver injury has been identified. This study aimed to investigate whether organoids can be used as tools to predict the risk of liver injury.MethodsWe examined the relationship between the clinical signs of L‐OHP‐induced liver injury and the responses of patient‐derived liver organoids in vitro. Organoids were established from noncancerous liver tissues obtained from 10 patients who underwent L‐OHP‐based chemotherapy and hepatectomy for colorectal cancer.ResultsOrganoids cultured in a galactose differentiation medium, which can activate the mitochondria of organoids, showed sensitivity to L‐OHP cytotoxicity, which was significantly related to clinical liver toxicity induced by L‐OHP treatment. Organoids from patients who presented with a high‐grade liver injury to the L‐OHP regimen showed an obvious increase in mitochondrial superoxide levels and a significant decrease in mitochondrial membrane potential with L‐OHP exposure. L‐OHP‐induced mitochondrial oxidative stress was not observed in the organoids from patients with low‐grade liver injury.ConclusionsThese results suggested that L‐OHP‐induced liver injury may be caused by mitochondrial oxidative damage. Furthermore, patient‐derived liver organoids may be used to assess susceptibility to L‐OHP‐induced liver injury in individual patients.
The use ofNibimaandImmunim, two Ghanaian herbal medicines in the management of mild COVID‐19: A case report
Authors: Boakye‐Yiadom Mavis , Yeboah Ronald , Offei‐Abrokwa David , Wilson Ekuwa Baisiwa , Darko Samuel Annang , Tamakloe Emmanuel 
Published: February 2024

Key Clinical MessageNibimaandImmunimmanages mild COVID‐19 in 7 days.AbstractCoronavirus Disease 2019 (COVID‐19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) can lead to severe complications and deaths. The search for phytotherapeutic agents to augment the fight against the current COVID‐19 pandemic is therefore of highest priority. A 52‐year‐old female with no history of chronic illness presented to our clinic facility with a 3 days loss of smell and headache which persisted after self‐medication. The patient tested positive for COVID‐19 in the SARS‐CoV‐2 Ag test as well as the Typhoid rapid antibody test. Routine laboratory tests were not remarkable. A 60 mL three times daily dose ofNibimaand 5 mL in 40 mL of warm water dose ofImmunimwere given to the patient for 7 days. Patient recovered sense of smell and regained appetite but cough although reduced persisted. She also tested negative for COVID‐19 after 7 days treatment. This case is the first documented case of COVID‐19 management with herbal medicines in Ghana. We strongly suggest a larger control trial on these products to ascertain these findings to repurpose them as viable treatments for COVID‐19.
The predictive value of laboratory parameters for no‐reflow phenomenon in patients with ST‐elevation myocardial infarction following primary percutaneous coronary intervention: A meta‐analysis
Authors: Wang LinLi , Huang ShuWei , Zhou Qiujun , Dou LiPing , Lin Dongming 
Published: February 2024

AbstractTo date, the predictive role of laboratory indicators for the phenomenon of no flow is unclear. Hence, our objective was to conduct a meta‐analysis to investigate the association between laboratory parameters and the risk of the no‐reflow phenomenon in patients with ST‐elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (PCI). This, in turn, aims to offer valuable insights for early clinical prediction of no‐reflow. We searched Pubmed, Embase, and Cochrane Library from the establishment of the database to October 2023. We included case‐control or cohort study that patients with STEMI following primary PCI. We excluded repeated publication, research without full text, incomplete information or inability to conduct data extraction and animal experiments, reviews, and systematic reviews. STATA 15.1 was used to analyze the data. The pooled results indicated that elevated white blood cell (WBC) count (odds ratio [OR] = 1.061, 95% confidence interval [CI]: 1.013–1.112), neutrophil count (OR = 1.324, 95% CI: 1.128–1.553), platelet (PLT) (OR = 1.002, 95% CI: 1.000–1.005), blood glucose (OR = 1.005, 95% CI: 1.002–1.009), creatinine (OR = 1.290, 95% CI: 1.070–1.555), total cholesterol (TC) (OR = 1.022, 95% CI: 1.012–1.032), d‐dimer (OR = 1.002, 95% CI: 1.001–1.004), and fibrinogen (OR = 1.010, 95% CI: 1.005–1.015) were significantly associated with increased risk of no‐reflow. However, elevated hemoglobin was significantly associated with decreased risk of no‐reflow. In conclusion, our comprehensive analysis highlights the predictive potential of various parameters in assessing the risk of no‐reflow among STEMI patients undergoing PCI. Specifically, WBC count, neutrophil count, PLT, blood glucose, hemoglobin, creatinine, TC,
d‐dimer, and fibrinogen emerged as significant predictors. This refined risk prediction may guide clinical decision‐making, allowing for more targeted and effective preventive measures to mitigate the occurrence of no‐reflow in this patient population.
Sequences in the myosin A rod interact with UNC‐89/obscurin and the zinc‐finger protein UNC‐98 during thick filament assembly and M‐line formation in C. elegans striated muscle
Authors: Almuhanna Sarah A. , Oishi Humayra Z. , Lee Kar Men , Hoppe Pamela E. 
Published: February 2024

AbstractThe M‐line of striated muscle is a complex structure that anchors myosin‐containing thick filaments and also participates in signaling and proteostasis. While the physical associations among many M‐line components have been defined, the mechanism of thick filament attachment is not completely understood. In Caenorhabditis elegans, myosin A is essential for viability and forms the site of M‐line attachment at the center of the filament, whereas myosin B forms the filament arms. Using a mutant myosin A that forms ectopic filaments, we examined interactions between myosin A and M‐line proteins in intact muscle cells. Ectopic myosin A recruits the giant kinase UNC‐89/obscurin, a presumed scaffolding protein, in an interaction that requires the zinc‐finger protein UNC‐98, but not UNC‐82/NUAK, UNC‐97/PINCH, or UNC‐96. In myosin A mutants, UNC‐89/obscurin patterning is highly defective in embryos and adults. A chimeric myosin containing 169 residues of the myosin A C‐terminal rod, coincident with the UNC‐98/ZnF binding site, is sufficient for colocalization of UNC‐89/obscurin and UNC‐98/ZnF in M‐line structures whereas a myosin chimera lacking these residues colocalizes with UNC‐89/obscurin in M‐lines that lack UNC‐98. Thus, at least two myosin A rod regions contribute independently to M‐line organization. We hypothesize that these M‐line‐organizing functions correspond to the essential “filament initiation function” performed by this isoform.
Employment outcomes of adolescent and young adult cancer survivors and their partners: A Dutch population‐based study
Authors: Dankers Polle W. , Janssen Silvie H. M. , van Eenbergen Mies , Siflinger Bettina M. , van der Graaf Winette T. A. , Husson Olga 
Published: February 2024

AbstractBackgroundThe aim of this population‐based registry study was to examine the impact of cancer on employment outcomes in adolescent and young adult (AYA) survivors and their partners and associated sociodemographic and clinical characteristics.MethodsA total of 2456 AYA cancer patients, diagnosed in 2013 and aged 18 through 39 years old, were selected from the Netherlands Cancer Registry and linked to employment data from Statistics Netherlands, from which 1252 partners of AYAs could be identified. For both patients and their partners, a control group with same age, migration background, and sex was selected. The impact (i.e., causal effect) was estimated by implementing a doubly robust difference‐in‐differences method, from 3 years before to 5 years after cancer diagnosis.ResultsPatients suffered a reduced employment probability (3.8 percentage points) and number of hours worked when employed (3.8%). This effect was larger for females, and individuals with a migration background, high tumor stage, or diagnosed with a central nervous system tumor/hematologic malignancy. In regard to employment, no significant effect could be found for the patients’ partners, although a 5.5 percentage‐point increase in employment probability was found in partners who were either unemployed or worked fewer than 400 hours.ConclusionsA cancer diagnosis significantly affects employment outcomes of AYA patients with cancer. Patients at risk should have access to services such as job counseling to help them return into society in the best possible way. No objective impact on partners’ employment outcomes was found; however, subjective well‐being was not taken into account.Plain Language Summary

This study estimated the causal effect of a cancer diagnosis on employment outcomes.
Adolescent and young adult cancer survivors face a reduction in both employment probability and the number of hours worked when employed.
Partners that were unemployed or worked the least number of hours a year before diagnosis had a 5.5 percentage‐point increased employment probability, but for other partners effects are small.
The 340B Program and oral specialty drugs for advanced prostate cancer
Authors: Faraj Kassem S. , Kaufman Samuel R. , Oerline Mary , Herrel Lindsey A. , Maganty Avinash , Caram Megan E. V. , Shahinian Vahakn B. , Hollenbeck Brent K. 
Published: February 2024

AbstractIntroductionExpensive oral specialty drugs for advanced prostate cancer can be associated with treatment disparities. The 340B program allows hospitals to purchase medications at discounts, generating savings that can improve care of the socioeconomically disadvantaged. This study assessed the effect of hospital 340B participation on advanced prostate cancer.MethodsThe authors performed a retrospective cohort study of Medicare beneficiaries with advanced prostate cancer from 2012 to 2019. The primary outcome was use of an oral specialty drug. Secondary outcomes included monthly out‐of‐pocket costs and treatment adherence. We evaluated the effects of 1) hospital 340B participation, 2) a regional measure vulnerability, the social vulnerability index (SVI), and 3) the interaction between hospital 340B participation and SVI on outcomes.ResultsThere were 2237 and 1100 men who received care at 340B and non‐340B hospitals. There was no difference in specialty drug use between 340B and non‐340B hospitals, whereas specialty drug use decreased with increased SVI (odds ratio, 0.95, p = .038). However, the interaction between hospital 340B participation and SVI on specialty drug use was not significant. Neither 340B participation, SVI, or their interaction were associated with out‐of‐pocket costs. Although hospital 340B participation and SVI were not associated with treatment adherence, their interaction was significant (p = .020). This demonstrated that 340B was associated with better adherence among socially vulnerable men.ConclusionsThe 340B program was not associated with specialty drug use in men with advanced prostate cancer. However, among those who were started on therapy, 340B was associated with increased treatment adherence in more socially vulnerable men.
Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2
Authors: Benedetti Daniel J. , Renfro Lindsay A. , Tfirn Ian , Daw Najat C. , Kalapurakal John A. , Ehrlich Peter F. , Khanna Geetika , Perlman Elizabeth , Warwick Anne , Gow Kenneth W. , Paulino Arnold C. , Seibel Nita L. , Grundy Paul , Fernandez Conrad V. , Geller James I. , Mullen Elizabeth A. , Dome Jeffrey S. 
Published: February 2024

AbstractBackgroundOn the fifth National Wilms Tumor Study, treatment for clear cell sarcoma of the kidney (CCSK) included combined vincristine, doxorubicin, cyclophosphamide, and etoposide (regimen I) plus radiation therapy (RT), yielding 5‐year event‐free survival (EFS) rates of 100%, 88%, 73%, and 29% for patients who had with stage I, II, III, and IV disease, respectively. In the Children’s Oncology Group study AREN0321 of risk‐adapted therapy, RT was omitted for stage I disease if lymph nodes were sampled, and carboplatin was added for stage IV disease (regimen UH‐1). Patients who had stage II/III disease received regimen I with RT.MethodsFour‐year EFS was analyzed for patients enrolled on AREN0321 and on those enrolled on AREN03B2 who received AREN0321 stage‐appropriate chemotherapy.ResultsEighty‐two patients with CCSK enrolled on AREN0321, 50 enrolled on AREN03B2 only. The 4‐year EFS rate was 82.7% (95% confidence interval [CI], 74.8%–91.4%) for AREN0321 and 89.6% (95% CI, 81.3%–98.7%) for AREN03B2 only (p = .28). When combining studies, the 4‐year EFS rates for patients who had stage I (n = 10), II (n = 47), III (n = 65), and IV (n = 10) disease were 90% (95% CI, 73.2%–100.0%), 93.4% (95% CI, 86.4%–100.0%), 82.8% (95% CI, 74.1%–92.6%), and 58.3% (95% CI, 34%–100.0%), respectively. There were no local recurrences among seven patients with stage I disease who were treated without RT. One stage I recurrence occurred in the brain, which was the most common site of relapse overall. Among patients with local stage III tumors, neither initial procedure type, margin status, nor lymph node involvement were prognostic.ConclusionsPatients with stage I CCSK had excellent outcomes without local recurrences when treated without RT. Patients with stage IV disease appeared to benefit from a carboplatin‐containing regimen, although their outcomes remained unsatisfactory. Further research is needed to improve outcomes for patients with advanced‐stage disease (ClinicalTrials.gov identifiers NCT00335556 and NCT00898365).
The Hydrogen Evolution Activity of BaZrS3, BaTiS3, and BaVS3 Chalcogenide Perovskites
Authors: Humphrey Nicholas , Tsung Alicia , Singh Shantanu , Irshad Ahamed , Zhao Boyang , Narayan Sri , Ravichandran Jayakanth , Mallikarjun Sharada Shaama 
Published: February 2024

AbstractChalcogenide perovskites are a class of materials with electronic and optoelectronic properties desirable for solar cells, infrared optics, and computing. The oxide counterparts of these chalcogenides have been studied extensively for their electrocatalytic and photoelectrochemical properties. As chalcogenide perovskites are more covalent, conductive, and stable, we hypothesize that they are more viable as electrocatalysts than oxide perovskites. The goal of this synthetic, experimental, and computational study is to examine the hydrogen evolution reaction (HER) activity of three Barium‐based chalcogenides in perovskite and related structures: BaZrS3, BaTiS3, and BaVS3. Potential energy surfaces for hydrogen adsorption on surfaces of these materials are calculated using density functional theory and the computational hydrogen electrode model is used to contrast overpotentials with experiment. Although both experiments and computations agree that BaVS3 is the most active of the three materials, high overpotentials of these materials make them less viable than platinum for HER. Our work establishes a framework for future studies in the chemical and electrochemical properties of chalcogenide perovskites.
Artificial Antigen‐Presenting Cell Fabrication for Murine T Cell Expansion
Authors: Omotoso Mary O. , Lanis Mara R. , Schneck Jonathan P. 
Published: February 2024

AbstractAntigen‐presenting cells (APCs), such as dendritic cells and macrophages, have a unique ability to survey the body and present information to T cells via peptide‐loaded major histocompatibility complexes (signal 1). This presentation, along with a co‐stimulatory signal (signal 2), leads to activation and subsequent expansion of T cells. This process can be harnessed and utilized for therapeutic applications, but the use of patient‐derived APCs can be complex and inefficient. Alternatively, artificial APCs (aAPCs) provide a simplified method to achieve T cell activation by presenting the two necessary stimulatory signals. This protocol describes the utilization of magnetic nanoparticles and stimulatory proteins to create aAPCs that can be employed for activating and expanding antigen‐specific T cells for both basic and translational immunology and immunotherapy studies. © 2024 Wiley Periodicals LLC.Basic Protocol 1: Protein and particle modification for aAPC fabricationBasic Protocol 2: aAPC validation by immunolabeling of conjugated proteinSupport Protocol 1: Quantification of aAPC stock concentrationBasic Protocol 3: Determination of aAPC usage for murine CD8+ T cell activationSupport Protocol 2: Isolation of murine CD8+ T cells